These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17540437)

  • 21. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
    Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
    J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
    Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
    Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
    Richter CE; Cocco E; Bellone S; Bellone M; Casagrande F; Todeschini P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Int J Gynecol Cancer; 2010 Dec; 20(9):1440-7. PubMed ID: 21370592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
    Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
    Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines.
    Bijman MN; van Berkel MP; Kok M; Janmaat ML; Boven E
    Anticancer Drugs; 2009 Jul; 20(6):450-60. PubMed ID: 19369859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.
    Roda JM; Joshi T; Butchar JP; McAlees JW; Lehman A; Tridandapani S; Carson WE
    Clin Cancer Res; 2007 Nov; 13(21):6419-28. PubMed ID: 17962339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.
    Lu Y; Li X; Liang K; Luwor R; Siddik ZH; Mills GB; Mendelsohn J; Fan Z
    Cancer Res; 2007 Sep; 67(17):8240-7. PubMed ID: 17804738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody.
    Watanabe Y; Asano R; Arai K; Shimomura I; Ogata H; Kawaguchi H; Hayashi H; Ohtsuka H; Yoshida H; Katayose Y; Egawa S; Nakanishi T; Umetsu M; Yasui H; Ishida T; Imai K; Kudo T; Unno M; Kumagai I
    Oncol Rep; 2011 Oct; 26(4):949-55. PubMed ID: 21743971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab.
    Patel D; Guo X; Ng S; Melchior M; Balderes P; Burtrum D; Persaud K; Luna X; Ludwig DL; Kang X
    Hum Antibodies; 2010; 19(4):89-99. PubMed ID: 21178280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma.
    Kawaguchi Y; Kono K; Mimura K; Mitsui F; Sugai H; Akaike H; Fujii H
    Br J Cancer; 2007 Aug; 97(4):494-501. PubMed ID: 17622245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients.
    Roberti MP; Rocca YS; Amat M; Pampena MB; Loza J; Coló F; Fabiano V; Loza CM; Arriaga JM; Bianchini M; Barrio MM; Bravo AI; Domenichini E; Chacón R; Mordoh J; Levy EM
    Breast Cancer Res Treat; 2012 Dec; 136(3):659-71. PubMed ID: 23065032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells.
    Kol A; Terwisscha van Scheltinga A; Pool M; Gerdes C; de Vries E; de Jong S
    Oncotarget; 2017 Jul; 8(28):45432-45446. PubMed ID: 28467975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade.
    Roberti MP; Juliá EP; Rocca YS; Amat M; Bravo AI; Loza J; Coló F; Loza CM; Fabiano V; Maino M; Podhorzer A; Fainboim L; Barrio MM; Mordoh J; Levy EM
    Eur J Immunol; 2015 May; 45(5):1560-9. PubMed ID: 25726929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The biological properties of cetuximab.
    Vincenzi B; Schiavon G; Silletta M; Santini D; Tonini G
    Crit Rev Oncol Hematol; 2008 Nov; 68(2):93-106. PubMed ID: 18676156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cetuximab sensitivity associated with oxaliplatin resistance in colorectal cancer.
    Ekblad L; Johnsson A
    Anticancer Res; 2012 Mar; 32(3):783-6. PubMed ID: 22399593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).
    Correale P; Marra M; Remondo C; Migali C; Misso G; Arcuri FP; Del Vecchio MT; Carducci A; Loiacono L; Tassone P; Abbruzzese A; Tagliaferri P; Caraglia M
    Eur J Cancer; 2010 Jun; 46(9):1703-11. PubMed ID: 20399639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy.
    Negri FV; Musolino A; Naldi N; Bortesi B; Missale G; Laccabue D; Zerbini A; Camisa R; Chernyschova N; Bisagni G; Loupakis F; Ruzzo A; Neri TM; Ardizzoni A
    Pharmacogenomics J; 2014 Feb; 14(1):14-9. PubMed ID: 23296156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor.
    Kimura H; Sakai K; Arao T; Shimoyama T; Tamura T; Nishio K
    Cancer Sci; 2007 Aug; 98(8):1275-80. PubMed ID: 17498200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities.
    Diaz Miqueli A; Blanco R; Garcia B; Badia T; Batista AE; Alonso R; Montero E
    Hybridoma (Larchmt); 2007 Dec; 26(6):423-31. PubMed ID: 18158788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship Between EGFR Expression in Oral Cancer Cell Lines and Cetuximab Antibody-dependent Cell-mediated Cytotoxicity.
    Nakamura H; Tamaki S; Yagyuu T; Yamakawa N; Hatake K; Kirita T
    Anticancer Res; 2019 Mar; 39(3):1275-1282. PubMed ID: 30842158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.